Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-01-04
2011-01-04
Saunders, David A (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S176100, C424S177100, C530S390500, C530S416000
Reexamination Certificate
active
07863426
ABSTRACT:
The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
REFERENCES:
patent: 5110913 (1992-05-01), Coan et al.
patent: 5118796 (1992-06-01), Prior et al.
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5429746 (1995-07-01), Shadle et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5795967 (1998-08-01), Aggarwal et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5877293 (1999-03-01), Adair et al.
patent: 5929212 (1999-07-01), Jolliffe et al.
patent: 5945098 (1999-08-01), Sarno et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6024938 (2000-02-01), Corbo et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6258562 (2001-07-01), Salfeld et al.
patent: 6448380 (2002-09-01), Rathjen et al.
patent: 6451983 (2002-09-01), Rathjen et al.
patent: 6489447 (2002-12-01), Basey et al.
patent: 6498237 (2002-12-01), Rathjen et al.
patent: 6509015 (2003-01-01), Salfeld et al.
patent: 6593458 (2003-07-01), Rathjen et al.
patent: 6870034 (2005-03-01), Breece et al.
patent: 7070775 (2006-07-01), Le et al.
patent: 7223394 (2007-05-01), Salfeld et al.
patent: 7250165 (2007-07-01), Heavner et al.
patent: 7276239 (2007-10-01), Le et al.
patent: 7541031 (2009-06-01), Salfeld et al.
patent: 7588761 (2009-09-01), Salfeld et al.
patent: 2003/0012786 (2003-01-01), Teoh et al.
patent: 2003/0049725 (2003-03-01), Heavner et al.
patent: 2003/0125247 (2003-07-01), Rosen et al.
patent: 2003/0161828 (2003-08-01), Abdelghany et al.
patent: 2003/0166869 (2003-09-01), Vendantham et al.
patent: 2003/0206898 (2003-11-01), Fischkoff et al.
patent: 2003/0219438 (2003-11-01), Salfeld et al.
patent: 2003/0229212 (2003-12-01), Fahrner et al.
patent: 2003/0235585 (2003-12-01), Fischkoff et al.
patent: 2004/0009172 (2004-01-01), Fischkoff et al.
patent: 2004/0033228 (2004-02-01), Krause et al.
patent: 2004/0120952 (2004-06-01), Knight et al.
patent: 2004/0126372 (2004-07-01), Banerjee et al.
patent: 2004/0126373 (2004-07-01), Banerjee et al.
patent: 2004/0131614 (2004-07-01), Banerjee et al.
patent: 2004/0136989 (2004-07-01), Banerjee et al.
patent: 2004/0136990 (2004-07-01), Banerjee et al.
patent: 2004/0136991 (2004-07-01), Banerjee et al.
patent: 2004/0151722 (2004-08-01), Banerjee et al.
patent: 2004/0166111 (2004-08-01), Kaymakcalan et al.
patent: 2004/0219142 (2004-11-01), Banerjee et al.
patent: 2005/0123541 (2005-06-01), Heavner et al.
patent: 2005/0249735 (2005-11-01), Le et al.
patent: 2005/0271654 (2005-12-01), Rinderknecht et al.
patent: 2006/0009385 (2006-01-01), Hoffman et al.
patent: 2006/0018907 (2006-01-01), Le et al.
patent: 2006/0024293 (2006-02-01), Salfeld et al.
patent: 2006/0083741 (2006-04-01), Hoffman et al.
patent: 2006/0153846 (2006-07-01), Krause et al.
patent: 2006/0246073 (2006-11-01), Knight et al.
patent: 2007/0003548 (2007-01-01), Heavner et al.
patent: 2007/0041905 (2007-02-01), Hoffman et al.
patent: 2007/0071747 (2007-03-01), Hoffman et al.
patent: 2007/0081996 (2007-04-01), Hoffman et al.
patent: 2007/0172897 (2007-07-01), Maksymowych et al.
patent: 2007/0202104 (2007-08-01), Banerjee et al.
patent: 2007/0292442 (2007-12-01), Wan et al.
patent: 2007/0298040 (2007-12-01), Le et al.
patent: 2008/0025976 (2008-01-01), Le et al.
patent: 2008/0118496 (2008-05-01), Medich et al.
patent: 2008/0131374 (2008-06-01), Medich et al.
patent: 2008/0166348 (2008-07-01), Kupper et al.
patent: 2008/0193466 (2008-08-01), Banerjee et al.
patent: 2008/0227136 (2008-09-01), Pla et al.
patent: 2008/0311043 (2008-12-01), Hoffman et al.
patent: 2009/0017472 (2009-01-01), Stuhlmuller et al.
patent: 2009/0028794 (2009-01-01), Medich et al.
patent: 2009/0110679 (2009-04-01), Li et al.
patent: 2009/0123378 (2009-05-01), Wong et al.
patent: 2009/0155205 (2009-06-01), Salfeld et al.
patent: 2009/0226530 (2009-09-01), Lassner et al.
patent: 2009/0239259 (2009-09-01), Hsieh et al.
patent: 2009/0258018 (2009-10-01), Medich et al.
patent: 2009/0271164 (2009-10-01), Peng et al.
patent: 2009/0291062 (2009-11-01), Fraunhofer et al.
patent: 2009/0304682 (2009-12-01), Hoffman et al.
patent: 2009/0317399 (2009-12-01), Pollack et al.
patent: 2010/0003243 (2010-01-01), Okun et al.
patent: 2010/0016557 (2010-01-01), Salfeld et al.
patent: 2010/0021451 (2010-01-01), Wong et al.
patent: 2010/0040630 (2010-02-01), Elden et al.
patent: 0101681 (1984-03-01), None
patent: 0186833 (1986-07-01), None
patent: 0212489 (1987-03-01), None
patent: 0351789 (1990-01-01), None
patent: 0366043 (1990-05-01), None
patent: 0492448 (1992-07-01), None
patent: 0614984 (1994-09-01), None
patent: 0659766 (1995-06-01), None
patent: 1174148 (2002-01-01), None
patent: 1254666 (2002-11-01), None
patent: 2279077 (1994-12-01), None
patent: WO-91/02078 (1991-02-01), None
patent: WO-92/11383 (1992-07-01), None
patent: WO-92/16553 (1992-10-01), None
patent: WO-93/06213 (1993-04-01), None
patent: WO-94/29347 (1994-12-01), None
patent: WO-95/23813 (1995-09-01), None
patent: WO 96/33208 (1996-10-01), None
patent: WO-97/04801 (1997-02-01), None
patent: WO-98/56418 (1998-12-01), None
patent: WO 99/57134 (1999-11-01), None
patent: WO-01/47554 (2001-07-01), None
patent: WO-02/012502 (2002-02-01), None
Graf et al, Bioseparation, 4, 7-20, 1994.
Abraham, Edward, et al., “Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients with Sepsis Syndrome,”JAMA, vol. 273(12):934-941 (1995).
Barbuto, J.A.M. et al. “Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes”Proc. Am. Assoc. Cancer Res,. 34:487, Abstr. 2904 (1993).
Bendtzen, K. et al. “Auto-antibodies to IL-1α and TNFα in Normal Individuals and in Infectious and Immunoinflammatory Disorders”The Physiological and Pathological Effects of Cytokines, 447-52 (1990).
Boekstegers, P., et al., “Repeated administration of a F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,”Shock, vol. 1(4):237-245 (1994).
Boyle, P. et al. “A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- α”Cell. Immunol., 152:556-68 (1993).
Boyle, P. et al. “The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFα on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope”Cell. Immunol., 152:569-81 (1993).
Brekke, Ole Henrik et al., “Therapeutic Antibodies for Human Diseases at the Dawn of the Twenty-first Century,”Nature, vol. 2:52-62 (2002).
Chow, A.W. et al. “Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFα, IL-1β, and IL-6 levels in patients with sepsis syndrome”Clinical Research, 42:2 299A (1994).
Cleland, Jeffrey L. et al., “A Specific Molar Ratio of Stabilizer to Protein is Required for Storage Stability of a Lyophilized Monoclonal Antibody,”Journal of Pharmaceutical Sciences, vol. 90(3):310-321 (2001).
Cohen, Jonathan, et al., “Intersept: An international, multicenter, placebo-controlled trial of monoclonal anitbody to human tumor necrosis factor-α in patients with sepsis,”Crit Care Med, vol. 24(9):1431-1440 (1996).
Cox, J.P.L. et al. “A directory of human germ-line Vκsegments reveals a strong bias in their usage”Eur. J. Immunol., 24(2):827-36 (1994).
Elliott, M.J. et al. “Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α”Arthritis&Rheumatism, 36(12):1681-90 (1993).
Feldmann, Marc et al., “Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned,”Annu. Rev. Immunol.,
Avgerinos George
Wan Min
Zarbis-Papastoitsis Gregory
Abbott Biotechnology Ltd.
Cowles Cristin Howley
Hanley, Esq. Elizabeth A.
McCarter & English LLP
Saunders David A
LandOfFree
Antibody purification does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody purification, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody purification will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678032